Net benefit and cost-effectiveness of universal iron-containing multiple micronutrient powders for young children in 78 countries: a microsimulation study.


Journal

The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665

Informations de publication

Date de publication:
08 2020
Historique:
received: 26 11 2019
revised: 05 05 2020
accepted: 05 05 2020
entrez: 26 7 2020
pubmed: 28 7 2020
medline: 1 9 2020
Statut: ppublish

Résumé

Universal home fortification of complementary foods with iron-containing multiple micronutrient powders (MNPs) is a key intervention to prevent anaemia in young children in low-income and middle-income countries. However, evidence that MNPs might promote infection raises uncertainty about whether MNPs give net health benefits and are cost-effective. We aimed to determined country-specific net benefit or harm and cost-effectiveness of universal provision of MNPs to children aged 6 months. We developed a microsimulation model to estimate net country-specific disability-adjusted life-years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs) due to anaemia, malaria, and diarrhoea averted (or increased) by provision of a 6-month course of MNPs to children aged 6 months, compared with no intervention, who would be followed up for an additional 6 months (ie, to age 18 months). Anaemia prevalence was derived from Demographic and Health Surveys or similar national surveys, and malaria and diarrhoea incidence were sourced from the Global Burden of Disease Study. Programme and health-care costs were modelled to determine cost per DALY averted (US$). Additionally, we explored the effects of reduced MNP coverage in a sensitivity analysis. 78 countries (46 countries in Africa, 20 in Asia or the Middle East, and 12 in Latin America) were included in the analysis, and we simulated 5 million children per country. 6 months of universal distribution of daily MNPs, assuming 100% coverage, produced a net benefit (DALYs averted) in 54 countries (24 in Africa, 19 in Asia and the Middle East, 11 in Latin America) and net harm in 24 countries (22 in Africa, one in Asia, and one in Latin America). MNP intervention provided a benefit on YLDs associated with anaemia, but these gains were attenuated and sometimes reversed by increases in YLLs associated with malaria and diarrhoea, reducing the benefits seen for DALYs. In the 54 countries where MNP provision was beneficial, the median benefit was 28·1 DALYs averted per 10 000 children receiving MNPs (IQR 20·6-40·4), and median cost per DALY averted was $3576 (IQR 2474-4918). DALY effects positively correlated with moderate and severe anaemia prevalence in Asia, the Middle East, and Latin America, but correlated inversely in Africa. Suboptimal coverage markedly reduced DALYs averted and cost-effectiveness. Net health benefits of MNPs vary between countries, are highest where prevalence of moderate and severe anaemia is greatest but infection prevalence is smallest, and are ameliorated when coverage of the intervention is poor. Our data provide country-specific guidance to national policy makers. International Union of Nutrition Sciences.

Sections du résumé

BACKGROUND
Universal home fortification of complementary foods with iron-containing multiple micronutrient powders (MNPs) is a key intervention to prevent anaemia in young children in low-income and middle-income countries. However, evidence that MNPs might promote infection raises uncertainty about whether MNPs give net health benefits and are cost-effective. We aimed to determined country-specific net benefit or harm and cost-effectiveness of universal provision of MNPs to children aged 6 months.
METHODS
We developed a microsimulation model to estimate net country-specific disability-adjusted life-years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs) due to anaemia, malaria, and diarrhoea averted (or increased) by provision of a 6-month course of MNPs to children aged 6 months, compared with no intervention, who would be followed up for an additional 6 months (ie, to age 18 months). Anaemia prevalence was derived from Demographic and Health Surveys or similar national surveys, and malaria and diarrhoea incidence were sourced from the Global Burden of Disease Study. Programme and health-care costs were modelled to determine cost per DALY averted (US$). Additionally, we explored the effects of reduced MNP coverage in a sensitivity analysis.
FINDINGS
78 countries (46 countries in Africa, 20 in Asia or the Middle East, and 12 in Latin America) were included in the analysis, and we simulated 5 million children per country. 6 months of universal distribution of daily MNPs, assuming 100% coverage, produced a net benefit (DALYs averted) in 54 countries (24 in Africa, 19 in Asia and the Middle East, 11 in Latin America) and net harm in 24 countries (22 in Africa, one in Asia, and one in Latin America). MNP intervention provided a benefit on YLDs associated with anaemia, but these gains were attenuated and sometimes reversed by increases in YLLs associated with malaria and diarrhoea, reducing the benefits seen for DALYs. In the 54 countries where MNP provision was beneficial, the median benefit was 28·1 DALYs averted per 10 000 children receiving MNPs (IQR 20·6-40·4), and median cost per DALY averted was $3576 (IQR 2474-4918). DALY effects positively correlated with moderate and severe anaemia prevalence in Asia, the Middle East, and Latin America, but correlated inversely in Africa. Suboptimal coverage markedly reduced DALYs averted and cost-effectiveness.
INTERPRETATION
Net health benefits of MNPs vary between countries, are highest where prevalence of moderate and severe anaemia is greatest but infection prevalence is smallest, and are ameliorated when coverage of the intervention is poor. Our data provide country-specific guidance to national policy makers.
FUNDING
International Union of Nutrition Sciences.

Identifiants

pubmed: 32710863
pii: S2214-109X(20)30240-0
doi: 10.1016/S2214-109X(20)30240-0
pmc: PMC9620416
mid: NIHMS1841695
pii:
doi:

Substances chimiques

Iron, Dietary 0
Micronutrients 0
Powders 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1071-e1080

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Value Health. 2012 Sep-Oct;15(6):835-42
pubmed: 22999133
Lancet. 2013 Jul 6;382(9886):29-40
pubmed: 23602230
Lancet Glob Health. 2015 Nov;3(11):e712-23
pubmed: 26475018
Lancet Glob Health. 2013 Aug;1(2):e77-e86
pubmed: 25104162
SSM Popul Health. 2016 Mar 07;2:95-104
pubmed: 29349132
Nutr J. 2011 Nov 24;10:129
pubmed: 22111770
Lancet. 2006 Jan 14;367(9505):133-43
pubmed: 16413877
Cochrane Database Syst Rev. 2004;(2):CD000363
pubmed: 15106149
Arch Pediatr Adolesc Med. 2012 May;166(5):404-10
pubmed: 22566538
Cochrane Database Syst Rev. 2011 Sep 07;(9):CD008959
pubmed: 21901727
Health Econ. 2004 May;13(5):405-15
pubmed: 15127421
Am J Clin Nutr. 2011 Mar;93(3):636-43
pubmed: 21270383
PLoS One. 2017 Aug 10;12(8):e0182951
pubmed: 28797115
Blood. 2014 Jan 30;123(5):615-24
pubmed: 24297872
Adv Nutr. 2016 Mar 15;7(2):349-56
pubmed: 26980818
Curr Dev Nutr. 2017 Jun 07;1(6):e001123
pubmed: 29955708
Food Nutr Bull. 2013 Dec;34(4):434-43
pubmed: 24605694
JAMA. 2013 Sep 4;310(9):938-47
pubmed: 24002280
BMJ. 2013 Mar 25;346:f1049
pubmed: 23529982
J Nutr. 2006 Apr;136(4):1068-71
pubmed: 16549479
Gut. 2015 May;64(5):731-42
pubmed: 25143342
Cochrane Database Syst Rev. 2016 Feb 27;2:CD006589
pubmed: 26921618
BMC Public Health. 2017 Sep 25;17(1):738
pubmed: 28946866
Public Health Nutr. 2005 Apr;8(2):117-32
pubmed: 15877905

Auteurs

Sant-Rayn Pasricha (SR)

Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia; Diagnostic Haematology, The Royal Melbourne Hospital, and Clinical Haematology at The Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia. Electronic address: pasricha.s@wehi.edu.au.

Adrian Gheorghe (A)

Global Health and Development, Department of Infectious Disease Epidemiology, Imperial College London, London, UK.

Fayrouz Sakr-Ashour (F)

Department of Nutrition and Food Science, University of Maryland, College Park, MD, USA.

Amrita Arcot (A)

Department of Nutritional Sciences, Pennsylvania State University, University Park, PA, USA.

Lynnette Neufeld (L)

Global Alliance for Improved Nutrition, Geneva, Switzerland.

Laura E Murray-Kolb (LE)

Department of Nutritional Sciences, Pennsylvania State University, University Park, PA, USA.

Parminder S Suchdev (PS)

Nutrition Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA; Department of Pediatrics and Emory Global Health Institute, Emory University, Atlanta, GA, USA.

Michael Bode (M)

School of Mathematics, Queensland University of Technology, Brisbane, QLD, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH